索磷布韦联合利巴韦林无干扰素方案治疗HIV-1感染者急性丙型肝炎:SWIFT-C研究
SWIFT-C是一项开放标签两队列临床试验,第一队列评估索磷布韦联合利巴韦林12周治疗HIV-1合并急性HCV感染的安全性和有效性。17名男性入组,59%获得SVR12(90%CI 36%-78%),未达到非劣效性,所有失败均为病毒复发(41%)。
要点
- 索磷布韦联合利巴韦林12周治疗HIV合并急性HCV基因1型感染复发率高。
- SVR12率为59%(90%CI 36%-78%),未达到预设非劣效性标准。
- 治疗失败均因病毒复发(41%),无提前停药。
核心结论
- 索磷布韦联合利巴韦林12周治疗HIV-1感染者急性HCV基因1型感染导致高复发率。
- DAA联合方案的初步研究提示应答率改善,但合适疗程仍不明确。
研究设计与样本
- SWIFT-C为开放标签、两队列临床试验,第一队列评估索磷布韦联合利巴韦林12周治疗HIV-1合并急性HCV感染的安全性和有效性。
- 第一队列计划入组17人,实际入组17名男性(11名西班牙裔,6名白人,中位年龄45岁)。
主要发现
- 88%为HCV基因1型感染,24%具有有利的IL28B CC基因型。
- 基线HCV RNA中位值为2 280 000 IU/mL(四分位距272 000-4 230 000)。
- 所有治疗失败均因病毒复发(41%),无提前停药。
- 达到SVR与复发者之间唯一差异因素是治疗结束时利巴韦林浓度。
临床怎么用
- 不推荐索磷布韦联合利巴韦林12周用于HIV-1感染者急性HCV基因1型感染的治疗。
- DAA联合方案可能改善应答,但最佳疗程需进一步研究确定。
局限性
- 第一队列样本量小(17人),且仅纳入男性。
- 未明确DAA联合方案治疗急性HCV的合适疗程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Historically, acute hepatitis C virus (HCV) infection was treated with shorter durations of interferon-containing therapies. In the era of direct-acting antivirals (DAAs), it is unclear whether the efficacy of treatment achieved in chronic infection can be maintained with abbreviated courses of therapy during the acute phase. METHODS: The sofosbuvir-containing regimens without interferon for treatment of acute HCV in HIV-1 infected individuals (SWIFT-C) is an open-label, 2-cohort clinical trial in which the first cohort assessed for the safety and efficacy of 12 weeks of sofosbuvir plus ribavirin for the treatment of acute HCV infection in participants with chronic human immunodeficiency virus type 1 (HIV-1) infection. This is a preplanned analysis of the first cohort, which had a planned accrual of 17 participants. RESULTS: Seventeen men (11 Hispanic, 6 white, median age 45 years) were enrolled. Most (88%) had HCV genotype-1 infection and few (24%) had the favorable IL28B CC genotype. Median baseline HCV RNA was 2 280 000 IU/mL (interquartile range, 272 000-4 230 000). Ten participants (59%) achieved the primary outcome of SVR12 (90% confidence interval, 36%-78%), failing to establish noninferiority. All treatment failures were due to viral relapse (41%). There were no premature treatment discontinuations. The only factor that differed between participants who achieved SVR vs those who relapsed was ribavirin concentration at the end of treatment. CONCLUSION: Sofosbuvir-ribavirin for 12 weeks for the treatment of acute HCV genotype-1 infection in HIV-1-infected persons results in a high relapse rate. Preliminary studies of DAA combination therapies suggest improved response rates, although the adequate duration of therapy remains unclear. CLINICAL TRIALS REGISTRATION: NCT02128217.
引用
- Naggie S, Marks KM, Hughes M, et al. Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. Clin Infect Dis. 2017. PMID: 28329053. doi:10.1093/cid/cix025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。